Corporate
Profile

Failed to register as Favorite Page
Failed to cancel as Favorite Page
This page is already registered as a Favorite Page
You can't add your company to your favorites.

Latest update: 22/11/2017 02:15:09

Cell Gentech Co., Ltd.

We research and develop gene transduced cell based medicine with self-renewing adipocytes.

We develop transduced adipocyte based medicine for diseases caused by the absence/deficiency of enzymes or protein. The medicine is prepared by introducing a gene that regenerates enzymes or protein into human adipocytes for the production of absent/deficient enzymes or protein. We reduce the burden on patients for yet-to-be-established effective treatments or current treatments. We contribute to medical care through the development and provision of treatment that not only cures the target disease, but also improves and maintains the quality of life (QOL) of patients. We acquired patents on the first adipocytes for gene therapy.

Inquiry

Other presentation

[Company strength]
We reduce the burden on patients for yet-to-be-established effective treatments or current treatments. We contribute to medical care through the development and provision of treatment that not only cures the target disease, but also improves and maintains the quality of life (QOL) of patients. As a pioneer of cell-based medicine, we provide transduced human adipocyte based medicine at an early stage. It stably supplies the body with therapeutic protein for rare diseases for which there is no treatment. We contribute to the health of patients suffering from intractable diseases.


[Business description]
We research and develop gene transduced cell based medicine with self-renewing adipocytes. We develop transduced adipocyte based medicine for diseases caused by the absence/deficiency of enzymes or protein. The medicine is prepared by introducing a gene that regenerates enzymes or protein into human adipocytes for the production of absent/deficient enzymes or protein.


[Industry]
Drug manufacturing


[Representative's message]
As a pioneer of cell-based medicine, we contribute to medical care through the provision of "transduced adipocyte based medicine," which is prepared by introducing a gene that regenerates therapeutic protein into human adipocytes. It is useful for intractable diseases mainly caused by inherently deficient or impaired protein having a physiological function. We contribute to improving the quality of life (QOL) of patients and their families suffering from intractable diseases. The technological basis of the transduced adipocyte based medicine can be applied to the research, development, and commercialization of cell-based and tissue-based medicine for future medical care. We contribute to medical care through our dedication to the health of patients around the world who are suffering from intractable diseases.


[Company structure for market development/overseas expansion]
We provide adipocyte-based medicine for gene therapy application. It is expected to be used for the treatment of diseases resulting from inborn errors of metabolism by correcting deficient/impaired enzymes or protein. It is also expected to be used for the treatment of intractable chronic diseases through the secretion of recombinant protein for correcting the state of the disease. It is our mission to quickly and widely provide the general-purpose technology of adipocytes for gene therapy to many patients suffering from intractable diseases. We are open to discussions on joint research and development with pharmaceutical companies, life science related companies, and research and development institutions.


[Awards and media coverage]
The Nikkan Kogyo Shimbun (8/24/2016); Yakuji Nippo No. 11763; Chiba Nippo Online (9/1/2016); The Sankei Shimbun (9/1/2016)


[Authorization/Certification]
(1) Japanese Patent No. 4879867; US 7820438 B2; EP 1541674 B1
(2) Japanese Patent No. 5806791


[Intellectual property]
(1) First adipocytes for gene therapy application; (2) Method for determining the suitability of a cell population for foreign gene transfer for the preparation of adipocytes for gene therapy application


This company is recommended by the following support organizations.

Kanto Head Office, SMRJ
Inquiry